Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Brain Behav Immun. 2012 Jul 14;26(8):1226–1238. doi: 10.1016/j.bbi.2012.07.002

Fig. 5.

Fig. 5

Mean percentage of splenic CD3-/DX5+ cells expressing the degranulation marker CD107a (A), 14hrs following 6 consecutive cycles of SDR compared to HCC animals. Mean percentage of activated splenic CD3-/DX5+/CD16+ cells expressing the degranulation marker CD107a (B), 14hrs following 6 consecutive cycles of SDR compared to HCC animals. * Indicates a significant difference from HCC animals (p’s≤0.05). Bars represent group means ± SEM.